Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Other uses of glucagon-like peptide-1 drugs GLP-1 receptor signaling is crucial in neuroinflammation and neurodegeneration after brain injuries, stroke, or neurodegenerative diseases.

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with mixed results from clinical trials.

Glucagon-like peptide-1 receptor agonist use may reduce alcohol consumption and improve outcomes in some individuals.

Scientists have gene-hacked mice to produce their own Ozempic-like drugs, paving a path for humans to do so themselves one ...

Given the scope of the risk, attention has turned to metabolic hormones that regulate appetite, satiety, and glucose metabolism, particularly glucagon-like peptide-1 (GLP-1).

According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.Results showed ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Glucagon-like peptide-1 (GLP-1) receptor agonists (also called “glutides”) are an effective treatment for patients with type 2 diabetes and chronic kidney disease In a randomized controlled trial of ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results.